Apollo Hospitals Enterprise Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings
- October 9, 2026
- Posted by: Lakshit Sharma
- Category: Market
Apollo Hospitals Enterprise share price Rs 7,935.50 (9 October 2026). Base target Rs 9,199, bull Rs 11,020, downside risk Rs 6,133. PE 50.75. 52W range Rs 6,696.50 to Rs 9,070.50.
Quick Answer
The Apollo Hospitals Enterprise share price target for 2027 is Rs 9,199, about 15.9% above the current price of Rs 7,935.50. The bull case is Rs 11,020, and the downside risk level, which is not a target, is Rs 6,133. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 46.9%, with the stock holding its PE of 50.75. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing an Apollo Hospitals Enterprise target price for 2027 should start with where the stock sits today. At Rs 7,935.50 on 9 October 2026, it is 12.5% below its 52-week high of Rs 9,070.50 and 18.5% above its 52-week low of Rs 6,696.50. That range spans 35% from low to high, so the entry point matters as much as the Apollo Hospitals Enterprise price forecast itself.
This article builds the Apollo Hospitals Enterprise share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 9,199 base case and the Rs 11,020 bull case were reached, along with a downside risk level of Rs 6,133.
Click Here – Get Free Investment Predictions
Apollo Hospitals Enterprise Stock Analysis: Company Overview and Key Stats
Apollo Hospitals Enterprise (NSE: APOLLOHOSP) has a market capitalisation of Rs 1,10,240 crore. In FY26 it reported revenue of Rs 25,420 crore and net profit of Rs 2,003 crore. The table collects the figures the Apollo Hospitals Enterprise share price target is built on.
| Metric | Value |
|---|---|
| Company | Apollo Hospitals Enterprise |
| NSE Ticker | APOLLOHOSP |
| CMP (9 October 2026) | Rs 7,935.50 |
| 52-Week High | Rs 9,070.50 |
| 52-Week Low | Rs 6,696.50 |
| Market Cap | Rs 1,10,240 crore |
| PE Ratio (TTM) | 50.75 |
| Industry PE | 62.79 |
| Price to Book | 11.63 |
| Return on Equity | 20.48% |
| Debt to Equity | 0.90 |
| EPS (TTM) | Rs 151.06 |
| Dividend Yield | 0.26% |
| 12-Month Base Target | Rs 9,199 |
| Bull Case | Rs 11,020 |
| Downside Risk Level (not a target) | Rs 6,133 |
Why Is Apollo Hospitals Enterprise Share Price Target Set at Rs 9,199 for 2027?
The base-case Apollo Hospitals Enterprise stock target of Rs 9,199 applies a PE multiple of 50.75 to a forward EPS estimate of Rs 181.27. That EPS assumes 20.0% yearly growth, the pace from FY24 to FY26, and puts the target 15.9% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Apollo Hospitals Enterprise Target Price: Five Years of Results
Apollo Hospitals Enterprise grew revenue from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew faster, from Rs 1,101 crore to Rs 2,003 crore (16.1% a year), which shows margin gains did part of the work and not just higher sales.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 14,740.80 | 1,101.10 | 73.42 | 11.75 |
| FY23 | 16,702.80 | 887.50 | 56.97 | 15.00 |
| FY24 | 19,165.50 | 935.00 | 62.50 | 16.00 |
| FY25 | 21,994.30 | 1,505.10 | 100.56 | 12.66 |
| FY26 | 25,420.10 | 2,002.70 | 134.94 | 20.00 |
FY26 revenue growth was 15.6%, close to the four-year average of 14.6%, and net profit moved up 33.1%. EPS rose from Rs 62.50 in FY24 to Rs 134.94 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Apollo Hospitals Enterprise converted 7.9% of FY26 revenue into net profit, against 6.8% in FY25, within a five-year range of 4.9% to 7.9%. EBITDA margin was 15.7% in FY26 versus 14.8% in FY25.
In the June 2026 quarter, revenue was Rs 7,092 crore, up 20.6% from the same quarter a year earlier, while net profit of Rs 610.40 crore was up 38.4%. EBITDA came in at Rs 1,141 crore, up 27.9% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.90, and shareholders’ equity grew from Rs 5,903 crore in FY22 to Rs 9,974 crore in FY26. Operating cash flow in FY26 was Rs 2,856 crore against capital expenditure of Rs 1,962 crore, leaving free cash flow of Rs 893.70 crore, or 0.8% of the current market capitalisation. In FY25 free cash flow was Rs 423.70 crore.
Valuation Check for the Apollo Hospitals Enterprise Stock Target: PE, Price to Book and ROE
At a PE of 50.75 against an industry PE of 62.79, Apollo Hospitals Enterprise trades at a discount to its industry. Price to book is 11.63 on a book value of Rs 659.33 per share, and return on equity is 20.48%. A PE of 50.75 equals an earnings yield of 2.0%, and the FY26 dividend of Rs 20.00 per share gives a yield of 0.26%.
Shareholding Pattern and Institutional Holding
Promoters held 28.02% of Apollo Hospitals Enterprise in September 2026, and promoter holding has stayed near 28.02% since September 2025. Foreign institutional investors (FII) held 43.18% and domestic institutions (DII) held 22.07%, which puts total institutional holding at 65.25%. FII holding fell from 44.20% in September 2025 to 43.18% in September 2026. Public shareholders own the remaining 6.72%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Apollo Hospitals Enterprise Share Price Targets for the Short Term and 12 Months
Short Term Apollo Hospitals Enterprise Stock Target Levels: Technical Setup
At Rs 7,935.50 on 9 October 2026, Apollo Hospitals Enterprise trades below its 50-day simple moving average of Rs 8,704.21 and below its 200-day exponential moving average of Rs 8,208.04. The 14-day RSI reads 25.1, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 8,208.04 (200-day exponential moving average) and the nearest support is Rs 6,696.50 (52-week low). A sustained move above Rs 8,208.04 would improve the short-term setup, while a close below Rs 6,696.50 would shift attention to the next support.
12 Month Apollo Hospitals Enterprise Target Price for 2027
The 12-month target for Apollo Hospitals Enterprise is Rs 9,199: forward EPS of Rs 181.27 at a PE of 50.75. That is 15.9% above Rs 7,935.50. It would also push the stock above its 52-week high of Rs 9,070.50.
How EPS Growth and PE Multiple Change the Apollo Hospitals Enterprise Target Price
| EPS Growth | PE 40.60 | PE 50.75 | PE 58.36 |
|---|---|---|---|
| 0.0% (EPS Rs 151.06) | Rs 6,133 | Rs 7,666 | Rs 8,816 |
| 20.0% (EPS Rs 181.27) | Rs 7,360 | Rs 9,199 | Rs 10,579 |
| 25.0% (EPS Rs 188.82) | Rs 7,666 | Rs 9,583 | Rs 11,020 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Apollo Hospitals Enterprise price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Apollo Hospitals Enterprise Stock Target in 2027
Bull Case Rs 11,020
The bull case Apollo Hospitals Enterprise price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 188.82, and a PE multiple that rises 15% to 58.36. That gives Rs 11,020, 38.9% above the current price and above the 52-week high of Rs 9,070.50, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 6,133
The downside risk level is not a target. It assumes EPS stays flat at Rs 151.06 and the PE falls 20% to 40.60. That gives Rs 6,133, 22.7% below the current price and below the 52-week low of Rs 6,696.50.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 25.0% | 58.36 | Rs 11,020 | +38.9% |
| Base Case | 20.0% | 50.75 | Rs 9,199 | +15.9% |
| Downside Risk | 0.0% | 40.60 | Rs 6,133 | -22.7% |
Key Risks to the Apollo Hospitals Enterprise Target Price for 2027
Growth Slowdown Risk for the Apollo Hospitals Enterprise Price Target
Revenue in the June 2026 quarter was up 20.6% year on year, and FY26 revenue growth was 15.6%. If growth slows from here, the EPS estimate behind the Apollo Hospitals Enterprise stock target will need revising.
Liquidity and Size Risk
Apollo Hospitals Enterprise has a market capitalisation of Rs 1,10,240 crore. Institutional holding is 65.25%, and promoters hold 28.02%. A company of this size trades with deep liquidity, so entry and exit are rarely a problem, and the larger risk is paying too much for slow earnings growth.
Valuation and Margin Risk
Net margin was 7.9% in FY26, so a small slip in costs moves profit noticeably. At a PE of 50.75 versus an industry PE of 62.79, a de-rating toward the downside-risk PE of 40.60 would cut the price even if earnings hold.
Market and Technical Risk
The stock trades 12.5% below its 52-week high, with an RSI of 25.1 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.
How to Invest in Apollo Hospitals Enterprise
Start with the live price and volume. Any Apollo Hospitals Enterprise share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 7,935.50 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Apollo Hospitals Enterprise’s PE, ROE, debt and shareholding in one place.
Check Apollo Hospitals Enterprise fundamentals on the Univest Screener
Then compare the three Apollo Hospitals Enterprise target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Apollo Hospitals Enterprise live price and get daily stock recommendations.
Conclusion
The Apollo Hospitals Enterprise share price target for 2027 is Rs 9,199 in the base case, with Rs 11,020 as the bull case. The support for that view is arithmetic you can check: EPS grew 46.9% a year over FY24 to FY26, and the stock trades at a PE of 50.75. The risks are equally concrete, including a stock that sits 12.5% below its 52-week high and a downside scenario that cuts the price 23% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Apollo Hospitals Enterprise Share Price Target 2027
What is the Apollo Hospitals Enterprise share price target for 2027?
Ans. The base-case Apollo Hospitals Enterprise share price target for 2027 is Rs 9,199, with Rs 11,020 as the bull case. The downside risk level, which is not a target, is Rs 6,133. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.
What is the Apollo Hospitals Enterprise share price today?
Ans. As of 9 October 2026, 12:52 PM IST, Apollo Hospitals Enterprise trades at Rs 7,935.50, up 3.52% on the day. The 52-week range is Rs 6,696.50 to Rs 9,070.50.
Is Apollo Hospitals Enterprise a buy or sell at the current price?
Ans. The data is mixed rather than one-sided: EPS has grown 46.9% a year over FY24 to FY26, but the stock is 12.5% below its 52-week high. Whether Apollo Hospitals Enterprise fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.
What are the bull case target and downside risk level for Apollo Hospitals Enterprise shares?
Ans. The bull case target is Rs 11,020, which assumes 25.0% EPS growth and a PE of 58.36. The downside risk level is Rs 6,133, which assumes flat EPS and a PE of 40.60. It marks a risk, not a target.
What are the main risks to the Apollo Hospitals Enterprise price target?
Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 1,10,240 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.
What is the PE ratio of Apollo Hospitals Enterprise and how does it compare with the industry?
Ans. The PE ratio of Apollo Hospitals Enterprise is 50.75 against an industry PE of 62.79. Price to book is 11.63 and return on equity is 20.48%. The base case in the Apollo Hospitals Enterprise price target holds this PE constant.
Who owns Apollo Hospitals Enterprise, and what is the promoter holding?
Ans. Promoters held 28.02% of Apollo Hospitals Enterprise in September 2026. FII held 43.18%, DII held 22.07% and the public held 6.72%.
What were Apollo Hospitals Enterprise’s latest quarterly results?
Ans. In the June 2026 quarter, Apollo Hospitals Enterprise reported revenue of Rs 7,092 crore (up 20.6% year on year) and net profit of Rs 610.40 crore (up 38.4%).